Gennova’s vaccine development initiative addresses four endemic diseases – malaria, tuberculosis, leishmaniasis, and flu. In this field, Gennova has national and international collaborations, e.g., University of Delhi South Campus (UDSC), PATH Malaria Vaccine Initiative (MVI), European Commission (under FP7 and Horizon 2020), Infectious Disease Research Institute (IDRI), National Institutes of Health (NIH), Johns Hopkins University (JHU), The London School of Hygiene & Tropical Medicine (LSHTM) and The Walter and Eliza Hall Institute (WEHI).
Gennova, in partnership with the US-FDA, McGill University, Ohio State University, Nekken Institute of Tropical Medicine, NIH, and JHU, has entered into a collaboration to develop and manufacture clinical-grade material of the genetically modified live attenuated Leishmania vaccine candidate, funded by the Global Health Innovative Technology Funds (GHIT), Japan. The program represents two important milestones for Gennova; having a collaborative vaccine program with the US-FDA is a significant testimony to Gennova’s capabilities and attributes and involves the formulation and manufacturing of a live attenuated vaccine to Gennova’s other vaccine programs, which focuses on recombinant-based products.
Recently, The Coalition for Epidemic Preparedness Innovations (CEPI) is supporting Gennova to develop novel RNA vaccine platform technologies against emerging infectious diseases.
